1218935-59-1

Basic information

• Product Name: (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE
• Synonyms: (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE;(2R)-2-(2,5-Difluorophenyl)pyrrolidine hydrochloride;(2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE-HCL;(R)-2-(2,5-difluorophenyl)pyrrolidine;Pyrrolidine, 2-(2,5-difluorophenyl)-, (2R)-
• CAS NO: 1218935-59-1
• Molecular Formula: C₁₀H₁₁F₂N
• Molecular Weight: 183.2
• EINECS: 227-251-0
• Mol File: 1218935-59-1.mol
• Article Data: 32

Chemical Properties

• Boiling Point: 213.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.164±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.02±0.10(Predicted)
• CAS DataBase Reference: (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE(1218935-59-1)
• EPA Substance Registry System: (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE(1218935-59-1)

Safety Data

• Hazardous Substances Data: 1218935-59-1(Hazardous Substances Data)

Usage

Description

(2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE is an organic compound with the molecular formula C11H12F2N. It is a chiral molecule with a specific configuration at the 2nd carbon atom, denoted as (2R). (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE is characterized by its fluorophenyl and pyrrolidine functional groups, which contribute to its unique chemical properties and potential applications.

Uses

Used in Pharmaceutical Industry:
(2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE is used as a key intermediate in the synthesis of imidazo[1,2-b]pyridazine compounds. These compounds are known to act as inhibitors of Trk kinases, which are a family of receptor tyrosine kinases involved in various cellular processes, including cell growth, differentiation, and survival. Inhibition of Trk kinases has been explored as a potential therapeutic strategy for the treatment of various cancers, as they are often overexpressed or dysregulated in malignant cells.
The application of (2R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE in the pharmaceutical industry is primarily focused on the development of novel Trk kinase inhibitors, which could potentially be used in the treatment of cancer. By targeting Trk kinases, these inhibitors may help to disrupt the signaling pathways that promote tumor growth and progression, offering a new avenue for cancer therapy.

Upstream product

• 617-86-7 triethylsilane 
• 1216260-42-2 4‐chloro‐1‐(2,5-difluorophenyl)butan-1-one 
• 1218935-58-0 (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate 
• 399-94-0 2-bromo-1,4-difluorobenzene 
• 1218935-60-4 (2R)-2-(2,5-difluorophenyl)pyrrolidine hydrochloride 
• 886503-15-7 rac-2-(2,5-difluorophenyl)pyrrolidine 
• 1919868-77-1 (R)-(+)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate 
• 540-36-3 para-difluorobenzene 
• 1979-36-8 2',5'-difluoroacetophenone 

Downstream Products

• 1218935-61-5 (R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-nitroimidazo[1,2-b]pyridazine 
• 1260840-74-1 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-2,3-dihydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260842-01-0 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-((S)-2,3-dihydroxypropoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260846-92-1 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260840-05-8 (R)-N-tert-butyl-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260840-10-5 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-N-(3-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260845-57-5 ethyl (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 1260846-28-3 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 

Relevant articles and documents

Zinc-Catalyzed Asymmetric Hydrosilylation of Cyclic Imines: Synthesis of Chiral 2-Aryl-Substituted Pyrrolidines as Pharmaceutical Building Blocks

The first successful enantioselective hydrosilylation of cyclic imines promoted by a chiral zinc complex is reported. In situ generated zinc-ProPhenol complex with silane afforded pharmaceutically relevant enantioenriched 2-aryl-substituted pyrrolidines in high yields and with excellent enantioselectivities (up to 99% ee). The synthetic utility of presented methodology is demonstrated in an efficient synthesis of the corresponding chiral cyclic amines, being pharmaceutical drug precursors to the Aticaprant and Larotrectinib. (Figure presented.).

FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR

A class of five-membered fused with six-membered heterocyclic compounds represented by formula I and a pharmaceutical composition, preparation, and an application thereof are disclosed. These compounds have TRK kinase inhibitory activity and can treat diseases related to TRK dysfunction.

SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR

Provided are a preparation and applications of a six-membered fused with six-membered heterocyclic compound, specifically, provided in the present invention is a compound as represented by formula I as follows, where the definitions of the groups are as described in the description. The compound has TRK kinase inhibiting activity and can serve as a pharmaceutical composition for treating TRK dysfunction-related diseases.